New Evernorth EnReachRx model expands its suite of GLP-1 solutions, works to improve patient outcomes and drive value

May 02, 25

Pharmacy in Focus: Navigating GLP-1 cost, demand and sustainability

With demand and utilization expanding, comprehensive clinical support and cost-management strategies are crucial to ensuring accessibility and safeguarding health care budgets.

March 25, 25

Research: Addressing cardiodiabesity at the household level could lower cost trend

Research suggests that combatting cardiodiabesity at the family and household level could further improve health outcomes and lower costs.

November 25, 24

Study: Cardiodiabesity prevention key to improving health outcomes and lowering costs

The Evernorth Research Institute analyzed aggregated and anonymized data of almost 5 million insured individuals to understand the prevalence of "cardiodiabesity" — a condition which encompasses cardi...

November 25, 24

Study: Progression of cardiodiabesity increases care utilization and costs

The Evernorth Research Institute’s latest cardiodiabesity report helps illustrate sites of care where preventive interventions can make the greatest financial impact.

November 25, 24

Understanding cardiodiabesity in women

As employers strive to maintain a healthy and productive workforce, addressing and understanding the prevalence of cardiodiabesity in women is critical.

Kasey Raetz, PharmD, November 11, 24